Triheptanoin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Triheptanoin
- Pharmacist Assessment Report
- Triheptanoin: From Long-Chain Fatty Acid Oxidation Disorders to Craniostenosis Cataract
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Triheptanoin: From Long-Chain Fatty Acid Oxidation Disorders to Craniostenosis Cataract
One-Sentence Summary
Triheptanoin is a medium odd-chain triglyceride (C7) that supplies heptanoate as an energy substrate, and it is marketed in Canada as DOJOLVI. The TxGNN model predicts it may be effective for craniostenosis cataract, but no clinical trials and no publications currently support this prediction. It rests on a model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Canadian license data (the mechanistic background suggests long-chain fatty acid oxidation disorders) |
| Predicted New Indication | Craniostenosis cataract |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, triheptanoin supplies heptanoate, which is converted to propionyl-CoA and then succinyl-CoA. This replenishes intermediates of the TCA cycle (anaplerosis). It is marketed for long-chain fatty acid oxidation disorders, where cells have difficulty producing energy from long-chain fats.
The link to the predicted indication is weak. No plausible pathway was identified that connects anaplerotic energy-substrate supply to cataract associated with craniosynostosis. The score of 0.9998 is a TxGNN model (deep learning) prediction. It likely reflects shared network neighbours across the cataract disease family rather than a specific mechanism.
The model also ranks many other cataract types highly, including diabetic, senile, nuclear, cortical, mature, immature and tetanic cataract. Diabetic cataract involves altered lens energy metabolism, so a theoretical argument exists there, but it is untested. No data are available on lens exposure after an oral triglyceride.
Other predicted indications:
| Rank | Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|---|
| 2 | Diabetes mellitus type 2 associated cataract | 0.9998 | L5 | Speculative link through lens energy metabolism |
| 3 | Mature cataract | 0.9998 | L5 | Advanced structural opacity, surgically treated |
| 4 | Immature cataract | 0.9998 | L5 | Untested theoretical argument |
| 5 | Tetanic cataract | 0.9998 | L5 | Driven by calcium disturbance, no link |
| 6 | Diabetic cataract | 0.9997 | L5 | Overlaps with rank 2 |
| 7 | Cortical cataract | 0.9997 | L5 | Ion and water balance, no link |
| 8 | Nuclear senile cataract | 0.9997 | L5 | Speculative |
| 9 | Senile cataract | 0.9997 | L5 | Likely family-level artefact |
| 10 | Antithrombin deficiency type 2 | 0.9997 | L5 | No interaction with the coagulation cascade |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02512556 | DOJOLVI | Not specified | Not specified |
Safety Considerations
- Drug Interactions: One interaction was identified in the compiled data: Orlistat (Major severity, DDInter). Orlistat reduces fat absorption, so it may interfere with absorption of a triglyceride product. Co-administration should be avoided or reviewed carefully.
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a TxGNN model (deep learning) score. There are no clinical trials, no publications and no plausible mechanism linking triheptanoin to craniosynostosis-associated cataract or to any other cataract type. Ocular delivery of an oral triglyceride is also unaddressed.
To proceed, the following is needed:
- Mechanism of action data for triheptanoin, to allow a proper mechanistic analysis
- Preclinical evidence (for example, lens culture or animal cataract models) showing a benefit of anaplerotic substrate supply
- Evidence of lens exposure or another rationale for ocular benefit after oral dosing
- The Health Canada package insert, to review the approved indication, warnings and contraindications
- A literature and trial search focused on cataract and metabolic substrate therapy, to confirm whether any supporting evidence exists
- A clinical review of the Major interaction with orlistat
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.